Article

ACA Ruling a Big Win for Mental Health

The King v. Burwell US Supreme Court decision yesterday means that people who could have lost mental health insurance coverage don't have to worry.

The King v. Burwell US Supreme Court decision yesterday means that people who could have lost mental health insurance coverage don't have to worry. They'll continue to have the benefits to refill their anti-depressant prescriptions, see a psychiatrist or psychotherapist, or get help from a drug counselor.

"Millions of Americans with serious mental health conditions are going to sleep much better tonight," Joel E. Miller, executive director and CEO of the American Mental Health Counselors Association, said after the decision came down.

A study compiled by his association showed that more than 2.7 million American adults in 34 states with mental health and substance abuse conditions would have become uninsured if the decision had outlawed the federal subsidies that help them obtain insurance under the Affordable Care Act (ACA).

Map of King v. Burwell impact

Image courtesy of the American Mental Health Counselors Association. An interactive version of this map is available here.

The court's validation of the ACA subsidies represents a "giant step forward in building a health care system for the future, a system that must include mental health," Mary Giliberti, executive director of the National Alliance on Mental Health (NAMI), added in a statement yesterday.

Although it wasn't part of the Supreme Court case, the ACA mandate on essential benefits also helps strengthen the mental health system, other advocates have noted. ACA insurance and some individual and small group plans must cover mental health treatment. That provision is especially important because many serious mental health conditions are life-long struggles, and are a leading cause of disabilities. Mental, neurological, and substance abuse disorders represent almost 20% of all disabilities in the US, according to National Institute of Mental Health Director Thomas Insel.

When people can't get access to mental health and substance abuse services because they don't have insurance and can't afford it, the personal cost in human suffering is high: divorce, unemployment, and even early death. Major mental illness can decrease life expectancy by 13 to 30 years, according to a 2006 study. A 2011 study found that someone with a previous heart attack who has major depression has 3 times the risk of a cardiac-related death. The National Institute of Mental Health has reported that as many people in the US die annually as a result of suicide as die from breast cancer.

The lack of access to insurance for mental health and substance abuse treatment comes at a high cost to society too. Car accidents, drug overdoses, suicides, and homicides could be reduced by better access to mental health and substance abuse care, according to a study in Utah by the national advocacy group Fight Crime: Invest in Kids.

In many communities, local jails have become the treatment centers of last resort for people with serious mental illnesses, such as schizophrenia, bipolar disorder, and major depression. Most of them have been charged with only minor, non-violent crimes, according to the Vera Institute of Justice. It reports that serious mental illness affects 14.5% of women and 31% of women in jails. One solution, Giliberti wrote in a recent blog, is getting "people living with mental illness the right help in their communities before the criminal justice system ever gets involved." She added that putting the mentally ill in jail in Wayne County, MI can cost 3 times as much as treating them in the community.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
© 2024 MJH Life Sciences

All rights reserved.